BridgeBio Pharma, Inc. Common Stock
BBIOStock
$80.30+76.00%52W
Market Cap$16.26B
P/E—
Div yield—
Beta0.98
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)1.84%
Price vs S&P 500 (4W)23.44%
VGM Score55.72
Market Capitalization$16.26B
Earnings Surprise History
Q1 26-0.84est. -0.69
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.28
4.27
4.21
4.20
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BBIOBridgeBio Pharma, Inc. Common Stock | F | A | B | $80.30 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
BridgeBio Pharma develops treatments for genetic diseases through a late-stage pipeline of four programs targeting Mendelian disorders, oncology, and gene therapy. Its lead candidate, Attruby (acoramidis), is an orally administered small molecule designed to stabilize transthyretin for the treatment of transthyretin amyloid cardiomyopathy.